Prevalence of Fabry disease in men with tinnitus and sensorineural hearing loss.

Fabry disease (FD) is a lysosomal storage disorder caused by pathogenic mutations in the alpha-galactosidase A (AGALA) encoding gene region. This rare disease affects several organs including the cochlea-vestibular system. Tinnitus and sensorineural hearing loss (SNHL) are reported among otoneurological symptoms. Early and correct diagnosis of FD is important with a view to available therapy. The aim of the study was to screen for alpha-galactosidase deficiency in men with tinnitus/SNHL. A prospective multicentric study including consecutive patients with SNHL confirmed by tone audiometry or tinnitus evaluated (10/2016-8/2019). The diagnosis of AGALA deficiency was done by dry blood spot method using a threshold of 1.2 µmol/l/h. Only men aged 18-60 were included. 181 patients were subject to evaluation. SNHL was reported in 126 (70%) patients, 50 (28%) patients had unilateral, 76 (42%) patients had bilateral SNHL. Tinnitus was found in 161 (89%) patients, unilateral in 96 (53%) and bilateral in 65 (36%) patients. Suspected FD was not detected in any patient; alpha-galactosidase The AGALA values ranged 1.5-8.8 µmol/l/h, an average of 3.4 µmol/l/h. None of the 181 patients participating in the study had AGALA levels below the threshold 1.2 µmol/l/h. The occurrence of tinnitus and sensorineural hearing loss in men appears to be an irrelevant clinical sign for FD systematic screening.

[1]  R. Garnotel,et al.  Maladie de Fabry : quand y penser ? , 2020 .

[2]  C. Wanner,et al.  Characterization of vertigo and hearing loss in patients with Fabry disease , 2018, Orphanet Journal of Rare Diseases.

[3]  A. Linhart,et al.  Fabry disease, an overview and the most common neurological manifestations , 2018 .

[4]  R. Holý,et al.  Hyperbaric oxygen therapy in tinnitus with normal hearing in association with combined treatment. , 2016, Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc.

[5]  J. Kuusisto,et al.  Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease , 2015, Drug design, development and therapy.

[6]  G. Paludetti,et al.  Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy. , 2010, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[7]  Shing‐Jong Lin,et al.  High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population , 2009, Circulation. Cardiovascular genetics.

[8]  Y. Chien,et al.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later‐onset GLA mutation c.936+919G>A (IVS4+919G>A) , 2009, Human mutation.

[9]  P. Elliott,et al.  Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa , 2007, Heart.

[10]  A. Mehta,et al.  Hearing loss in Fabry disease: data from the Fabry Outcome Survey , 2006, European journal of clinical investigation.

[11]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.

[12]  M. Audran,et al.  Fabry disease: a review. , 2004, Joint, bone, spine : revue du rhumatisme.

[13]  A. Mehta,et al.  Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy , 2003, Journal of Inherited Metabolic Disease.

[14]  K. Macdermot,et al.  Hearing improvement in patients with Fabry disease treated with agalsidase alfa , 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[15]  S. Packman,et al.  Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.

[16]  K. Macdermot,et al.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males , 2001, Journal of medical genetics.

[17]  S. Mulgaonkar,et al.  Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance. , 2000, Transplantation.

[18]  G. Hughes,et al.  Sudden sensorineural hearing loss. , 1996, Otolaryngologic clinics of North America.

[19]  H. Schuknecht,et al.  Cochlear Pathology in Presbycusis , 1993, The Annals of otology, rhinology, and laryngology.

[20]  M. Paparella,et al.  Otologic Histopathology of Fabry's Disease , 1989, The Annals of otology, rhinology, and laryngology.

[21]  S. Hegemann,et al.  Fabry disease and the ear , 2006 .

[22]  F. Akdaş,et al.  Idiopathic sudden sensorineural hearing loss , 2006 .

[23]  D. Germain A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. , 2001, Contributions to nephrology.

[24]  Mattox De,et al.  Idiopathic sudden sensorineural hearing loss. , 1989, The American journal of otology.